SUPN
Supernus Pharmaceuticals Inc
42.00$
-2.1%
vs. previous close
Closing price · As of: Sep 18, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 4.7% | 5.8% | 5.6% | 5.0% | 3.8% | 4.2% | 10.1% | 12.9% | 13.1% | 13.8% | 11.8% | 10.4% | |
| 95.3% | 94.2% | 94.4% | 95.0% | 96.2% | 95.8% | 89.9% | 87.1% | 86.9% | 86.2% | 88.2% | 89.6% | |
| 16.0% | 20.2% | 19.9% | 16.4% | 21.8% | 17.6% | 14.6% | 15.6% | 11.2% | 15.1% | 16.4% | 14.8% | |
| 47.3% | 48.4% | 39.1% | 34.4% | 28.5% | 29.9% | 12.7% | 18.1% | 16.4% | 39.0% | 37.4% | 27.4% | |
| 75.4% | 81.9% | 69.2% | 62.0% | 60.9% | 57.9% | 56.5% | 72.2% | 80.0% | 87.1% | 75.9% | 94.8% | |
| 19.9% | 12.2% | 25.2% | 32.9% | 35.3% | 37.8% | 33.4% | 14.8% | 6.9% | -0.9% | 12.3% | -5.1% | |
| 4.6% | 3.3% | 2.4% | 0.5% | 4.4% | 5.8% | 4.6% | 4.0% | 1.1% | 0.4% | 0.0% | 0.0% | |
| 16.3% | 10.4% | 23.4% | 33.3% | 34.3% | 37.6% | 32.4% | 12.6% | 9.1% | 0.5% | 14.8% | -6.8% | |
| 3.3% | 0.7% | -19.0% | 14.3% | 7.1% | 8.8% | 8.0% | 3.4% | 0.0% | 0.2% | 3.6% | -1.5% | |
| 16.3% | 9.7% | 42.4% | 19.0% | 27.1% | 28.8% | 24.4% | 9.2% | 9.1% | 0.2% | 11.2% | -5.4% | |
| -3.6% | 15.1% | 26.3% | 35.6% | 37.1% | 45.9% | 40.5% | 22.3% | 23.0% | 14.8% | 26.9% | 5.9% |
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.